Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab vs Mepolizumab/Benralizumab in Severe Asthma
NCT04718389Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of depemokimab in asthma, sponsored by GSK. Started Jan 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04718389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718389.